An observational study in Genetic Disease and Metabolic Abnormalities, sponsored by Fondazione IRCCS San Gerardo dei Tintori. Not yet recruiting at 1 site in Italy. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Fondazione IRCCS San Gerardo dei Tintori · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Genetic Diseases, Inborn with a site in Italy — 22 open to participants now, 26 under way, 7 of them phase 3. Genetic Diseases, Inborn · Italy.
Among the 65 studies in Genetic Diseases, Inborn with a site in Italy, this one is the 5th largest by planned enrollment of the 19 observational ones that give a count, is one of 5 that started in 2026, is one of 19 observational ones, reaches primary completion later than 16 of the 25 other live ones, and was the 65th registered.
585 studies on the registry are indexed under Genetic Diseases, Inborn; 159 are open to participants now.
Browse Genetic Diseases, Inborn studies →22 of the 65 studies in Genetic Diseases, Inborn with a site in Italy are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Italy, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
BioMarin Pharmaceutical · Sites in Italy, United States, Australia and 6 more countries
Ages 2–17
IRCCS Eugenio Medea · Sites in Italy
Ages 11–39
CSL Behring · Sites in Italy, United States, Belgium and 4 more countries
Ages 18+
Imagine Institute · Sites in Italy, Austria, Belgium and 8 more countries
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.
This study: 1 Month to 18 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 18 · Phase 3 25
First in 1997; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 152 across 240 observational studies indexed under Genetic Diseases, Inborn.
Median enrollment 74 across the 46 interventional studies, 200 across the 19 observational. Of the 37 that completed or were terminated, 21 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 65 have an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS San Gerardo dei Tintori is the lead sponsor of 11 studies on the registry; 9 are open to participants now.
Fondazione IRCCS San Gerardo dei Tintori has 1 study filed under Genetic Diseases, Inborn — fewer than ten, so there is no comparison to draw.
6 of the studies in Genetic Diseases, Inborn with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT07884227Istituto Giannina GasliniMulti-Omics Genetic Investigation Strategies to Enhance the Diagnostic Workflow for Rare Diseases | 2026-12-31 |
| NCT07877688Istituto Giannina GasliniExome and Genome Sequencing of DNA Samples, as Required by Specific Research Projects and the Diagnostic Needs of the Gaslini Institute, to Be Performed Within the Framework of the "Joint Genomic Lab" Established Between IGG and IIT | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 65 studies in Genetic Diseases, Inborn with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study aims to describe and characterize the multidimensional care needs of children and adolescents aged 1 month to 18 years with rare genetic and metabolic diseases, with particular emphasis on the identification of pediatric palliative care needs.
The study seeks to answer the question of which clinical, physical, psychological, social, and care-related needs characterize this population, and to what extent these needs are associated with complex care requirements and potential eligibility for pediatric palliative care.
Additional objectives include assessing pain, sleep disturbances, psychological well-being, quality of life, physical and social functioning, medication-related adverse events, symptom interference with daily life, and caregiver burden. The study will also explore individual care needs and the transition from pediatric to adult healthcare services.
A subgroup of approximately 150 participants will undergo longitudinal assessments every three months for up to 12 months to describe changes in care needs over time and identify factors potentially associated with worsening clinical and care complexity. Furthermore, a qualitative substudy involving caregivers and adolescents will explore the lived experience of illness and the meaning attributed to the disease by children and their families through semi-structured interviews.
Overall, the study aims to provide a comprehensive understanding of the care needs and illness experience of children with rare genetic and metabolic diseases, supporting the early identification of complex needs and the development of more personalized, proactive, and family-centered care pathways.
Study participants will be consecutively recruited from the outpatient clinics of Metabolic Diseases and Clinical Genetics at Fondazione IRCCS San Gerardo dei Tintori, a tertiary referral hospital located in Monza, Italy. The study population will include patients attending these clinics for specialist assessment and follow-up. For the qualitative substudy, caregivers and eligible adolescent patients will be selected from the same clinical population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AccaPed Total Score for the Assessment of Complex Pediatric Palliative Care Needs
The total score of the AccaPed scale will be used to assess complex pediatric palliative care needs. The assessment will be performed at study enrollment in all participants. In a subgroup of approximately 150 participants, the assessment will be repeated every three months for 12 months to describe changes in care needs over time.
Time frame: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.
Paediatric Palliative Care Needs
The Paediatric Palliative Screening Scale (PaPaS) will be used to assess pediatric palliative care needs in participants aged 1 to 18 years. The assessment will be performed at study enrollment in all eligible participants. In a subgroup of approximately 150 participants, the assessment will be repeated every three months for 12 months to evaluate changes in palliative care needs over time.
Time frame: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.
Pain Intensity Assessment
Pain intensity will be assessed using age- and cognitive status-appropriate validated tools: the Revised Face, Legs, Activity, Cry, Consolability scale (r-FLACC), the Face, Legs, Activity, Cry, Consolability scale (FLACC), the Wong-Baker FACES Pain Rating Scale, or the Numeric Rating Scale (NRS). The most appropriate instrument will be selected according to the participant's age and cognitive status. The assessment will be performed at study enrollment in all eligible participants and repeated in a subgroup of approximately 150 participants every three months for 12 months.
Time frame: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.
Assessment of Nociceptive Pain Phenotype
The nociceptive pain phenotype will be characterized through the assessment of central and peripheral sensitization using simplified Quantitative Sensory Testing (QST), the identification of nociplastic pain according to the definition of the International Association for the Study of Pain (IASP), and the assessment of neuropathic pain using the PainDETECT Questionnaire (PD-Q). The assessment tools will be selected according to the participant's age and cognitive status. Assessments will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months, where applicable.
Time frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants, where applicable.
Sleep Disturbances Assessment
Sleep disturbances will be assessed using the Sleep Disturbance Scale for Children (SDSC) in participants aged 6 months to 18 years. The questionnaire will be completed by the researcher or caregiver. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.
Time frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Psychological Well-being Assessment
Psychological aspects will be assessed using the Revised Children's Anxiety and Depression Scale (RCADS) in participants aged 8 to 18 years. The questionnaire will be completed by the researcher, caregiver, or participant, as appropriate. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.
Time frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Pain Catastrophizing Assessment
Pain catastrophizing will be assessed using the Pain Catastrophizing Scale for Children (PCS-C) in participants aged 8 to 18 years. The questionnaire will be completed by the participant. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.
Time frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Health-Related Quality of Life Assessment
Health-related quality of life will be assessed using the Pediatric Quality of Life Inventory (PedsQL) in participants aged 2 to 18 years. The appropriate version will be selected according to age, with the possibility of using the parent-proxy form for participants unable to complete the questionnaire because of age or cognitive impairment. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.
Time frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Physical Function Assessment
Physical function will be assessed using the Gross Motor Function Classification System (GMFCS) in participants aged 1 to 18 years and the Function Disability Inventory (FDI) in participants aged 8 to 18 years. The FDI parent-report version may be used when required for children with cognitive difficulties. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.
Time frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Social Function Assessment
Social function will be assessed using the KIDSCREEN-27 in participants aged 8 to 18 years, using the self-report or parent-proxy version as appropriate. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.
Time frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Pharmacological Treatment, Perceived Benefit, and Adverse Events
Pharmacological treatment will be characterized by recording the number and type of medications taken, the perceived benefit of treatment, and any reported medication-related adverse events. Treatment-related changes will also be assessed using the Patient Global Impression of Change (PGIC) in participants aged 8 to 18 years and the Observer Global Impression of Change (OGIC) parent-proxy form in participants with cognitive impairment. Assessments will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.
Time frame: At study enrollment for all participants; every three months for 12 months in a subgroup of approximately 150 participants.
Symptom Interference with Daily Life
The impact of symptoms on daily life will be assessed using the Symptom Screening in Pediatrics Tool (SSPedi). The self-report version will be used in participants aged 8 to 18 years, while the parent-proxy version will be used in participants aged 2 to 18 years, according to the participant's ability to complete the questionnaire. Assessments will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.
Time frame: At study enrollment for all eligible participants; every three months for 12 months in a subgroup of approximately 150 participants.
Caregiver Burden Assessment
Caregiver burden will be assessed using the Caregiver Burden Inventory (CBI), completed by the caregiver. The assessment will be performed at study enrollment and repeated in a subgroup of approximately 150 participants every three months for 12 months.
Time frame: At study enrollment for all participants with an eligible caregiver assessment; every three months for 12 months in a subgroup of approximately 150 participants.
Transition to Adult Healthcare Services
The transition to adult healthcare services will be assessed by recording the proportion of patients requiring transfer to adult care, the proportion of patients for whom the transfer process has been initiated by 17 years and 6 months of age, and the proportion of patients effectively transferred to adult healthcare services upon reaching 18 years of age.
Time frame: During the 36-month study period.
Individual Nursing Care Needs Classified According to ICNP
Individual care needs will be identified and classified using the International Classification for Nursing Practice (ICNP), a standardized terminology for describing and documenting nursing practice. The assessment will support the systematic description of participants' individual nursing care needs.
Time frame: At baseline; repeated every three months for 12 months in a subgroup of approximately 150 participants
Illness Experience and Meaning Attributed to the Disease by Children and Families
The illness experience and the meaning attributed to the disease by children and their families will be explored through semi-structured interviews involving a subgroup of caregivers and adolescent participants aged 12 years or older. Interviews will be conducted until data saturation is achieved. The qualitative data will be analyzed to identify relevant themes concerning illness experience and care.
Time frame: Until data saturation is achieved during the study period.
Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.
Of 94 non-industry observational studies under Genetic Diseases, Inborn, half reached primary completion within 124 months of starting (the median), counting those still running; a quarter within 46. This study's planned 36 months is below that.
Counting every sponsor, half of 128 studies reached it within 110 months; a quarter within 46 and three quarters within 193.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS San Gerardo dei Tintori